ECE2017 Eposter Presentations: Thyroid Thyroid (non-cancer) (260 abstracts)
Development of hypoparathyroidism due to targeted therapies
Asena Gokcay Canpolat 1 , Berna Imge Aydogan 2 , Sule Canlar 1 , Sevim Gullu 1 & Murat Faik Erdogan 1
1Department of Endocrinology and Metabolism, Ankara University Faculty of Medicine, Ankara, Turkey; 2Batman State Hospital, Batman, Turkey.
Due to inhibition affect on proliferation, motility, resistance to apoptosis and growth of metastasis, the epidermal growth factor receptor (EGFR) inhibitor erlotinib and vascular endothelial growth factor receptor (VEGF) and EGFR inhibitor vandetanib are viable treatment options for treatment of advanced non-small cell lung cancer and thyroid cancer respectively. Advanced non-small cell lung carcinomas (NSCLC) or medullary and differentiated thyroid carcinomas (MTC and DTC) may present with bone metastatis in the presence of bone pain, elevated serum calcium or elevated alkaline phosphatase levels. We, hereby represent two patients who had diagnosis of NSCLC and MTC with bone metastatis, both treated with EGFR inhibitors and presented surprisingly with hypocalcemia in our outpatient clinic as a result of hypoparathyroidism. Sudden declines in calcium levels after initiating EGFR inhibitors contrary to the evidence of bone metastasis in these cases preoccupied that these agents may prevent parathyroid cell growth and decreased PTH levels lead to hypocalcemia.
Volume 49
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more